Newark, Del.-based ChristianaCare’s Center for Heart & Vascular Health is the first facility in the state to offer two FDA-approved, minimally invasive procedures for tricuspid valve disease.
The TriClip device repairs a leaky tricuspid valve by clipping its flaps together, while the Evoque valve replacement anchors a new valve inside the patient’s existing one. Both procedures are performed via catheter, avoiding open-heart surgery and allowing most patients to go home the next day, according to a Sept. 17 news release from the health system.
Erin Fender, MD, and James Hopkins, MD, debuted the TriClip procedure in August, and the physicians performed the first Evoque procedure at ChristianaCare in September, the release said.
“[ChristianaCare now offers] every FDA-approved therapy for tricuspid valve disease, which means we can tailor treatment to each patient,” Kirk Garratt, MD, the center’s medical director, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.